Lenvatinib or regorafenib for advanced liver cancer after immunotherapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests two targeted therapy drugs, lenvatinib or regorafenib, for people with advanced liver cancer that got worse after first treatment with immunotherapy. It aims to see if these drugs can help when immunotherapy stops working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have advanced liver cancer that cannot be removed by surgery or cured by other treatments.
- You have already received immunotherapy as your first cancer treatment and the cancer continued to grow.
- You have not been treated with lenvatinib or regorafenib before.
- You have not had more than one prior treatment for your advanced liver cancer.
- Your liver function is good enough (Child-Pugh A or B) and you are in generally good health (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (regorafenib) for people with advanced hepatocellular carcinoma (liver cancer) that has gotten worse after or during first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer.
This study tests a combination of three drugs—TUDCA (a bile acid supplement), camrelizumab (an immunotherapy), and regorafenib (a targeted therapy)—for people with advanced liver cancer that has continued to grow after earlier immunotherapy plus Avastin treatment. The goal is to see if this new mix can help stop the cancer from growing.
This trial tests whether adding lenalidomide (a drug that boosts the immune system) to your current targeted therapy and immunotherapy can help advanced liver cancer that has progressed after previous treatments. You would be eligible if your cancer has already been treated with at least two prior drug combinations and initially responded before growing back.
This trial tests whether regorafenib, a targeted cancer drug, can help patients with advanced liver cancer whose disease progressed after or couldn't tolerate first-line immunotherapy. The goal is to see if this drug can slow or shrink the cancer.
This trial tests whether regorafenib, a targeted cancer drug, can help patients with advanced liver cancer (HCC) whose disease got worse or stopped tolerating lenvatinib, an earlier treatment. The goal is to see if switching to regorafenib can slow or shrink the cancer.
This trial tests whether adding trastuzumab to the standard drug regorafenib works better than regorafenib alone for people with advanced liver cancer that has grown after initial treatment. It is for those who have already received a type of immunotherapy combined with a targeted drug (like atezolizumab + bevacizumab).
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.